APOLLO ENDOSURGERY INC. overview

MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric Devices AUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year (1) , was selected as 2022 Top Story in Gastroenterology. (2) Additionally, the American...

Boston Scientific to acquire Apollo for $10.00 per share in cash AUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of...

OverStitch has new indications for use statement under CE-Mark, including indications for defect closure, stent fixation, endoscopic sleeve gastroplasty and transoral outlet reduction AUSTIN, TX / ACCESSWIRE / November 21, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has successfully transitioned its legacy products to CE Mark under the European Medical Device...

AUSTIN, TX / ACCESSWIRE / November 7, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that its senior management team will host investor meetings at four investor conference events during November and December 2022. Event: Stifel 2022 Healthcare Conference Date: Wednesday, November 16, 2022 Presentation: 2:25 p.m. Eastern Time; 1x1 meetings available Location: Lotte New...

Grew global revenue 20% GAAP, 24% in constant currency Received FDA authorization for Apollo ESG TM and Apollo REVISE TM systems for treating patients with obesity AUSTIN, TX / ACCESSWIRE / November 1, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2022 and recent corporate highlights. Third Quarter 2022 Selected...

AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides...

Patients undergoing ESG achieved 24% total body weight loss in a bariatric surgery practice in a community setting. AUSTIN, TX / ACCESSWIRE / August 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that the endoscopic sleeve gastroplasty (ESG) procedure was featured in a 2022 Top 10 Paper at the International Federation for the Surgery of Obesity and Metabolic Disorders...

Grew global revenue 16% (20% in constant currency) as adoption increased across all product lines Secured FDA marketing authorization for Apollo ESG TM and Apollo REVISE TM AUSTIN, TX / ACCESSWIRE / August 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2022 and recent corporate highlights. Second Quarter 2022...